The IBB chart settings shown below allow you to select time intervals of 1 min, 30 mins, an hour or by day - week - month. There is also the ability to change the IBB chart style to candles, hollow candles, bars, lines or add various indicators. You can even add a symbol and compare history.
The IBB stock resources shown below were gathered to cut back on time by allowing you to visit multiple sites at once. For your convenience each link clicked will open in a window. In addition to the individual links there is a button at the bottom that will allow you to open all the links at the same time. Note opening all links at once may not work with all browsers. Some browsers block multiple windows, to resolve this please allow that site to use pop-ups.
|View IBB Detailed Price Forecast - CNN Money||View IBB Detailed Summary - Google Finance|
|View IBB Detailed Summary - Yahoo! Finance||View IBB Stock Research & Analysis - Zacks.com|
|View IBB Trends & Analysis - Trade-Ideas||View IBB Major Holders - Barrons|
|View IBB Call Transcripts - NASDAQ||View IBB Breaking News & Analysis - Seeking Alpha|
|View IBB Annual Report - CompanySpotlight.com||View IBB OTC Short Report - OTCShortReport.com|
|View IBB Fundamentals - TradeKing||View IBB SEC Filings - Bar Chart|
|View Historical Prices for IBB - The WSJ||View Performance/Total Return for IBB - Morningstar|
|View the Analyst Estimates for IBB - MarketWatch||View the Earnings History for IBB - CNBC|
|View the IBB Earnings - StockMarketWatch||View IBB Buy or Sell Recommendations - MacroAxis|
|View the IBB Bullish Patterns - American Bulls||View IBB Short Pain Metrics - ShortPainBot.com|
|View IBB Stock Mentions - StockTwits||View IBB Stock Mentions - PennyStockTweets|
|View IBB Stock Mentions - Twitter||View IBB Investment Forum News - Investor Hub|
|View IBB Stock Mentions - Yahoo! Message Board||View IBB Stock Mentions - Seeking Alpha|
|View Insider Transactions for IBB - SECform4.com||View Insider Transactions for IBB - Insider Cow|
|View IBB Major Holdings Summary - CNBC||View Insider Disclosure for IBB - OTC Markets|
|View Insider Transactions for IBB - Yahoo! Finance||View Institutional Holdings for IBB - NASDAQ|
|View IBB Stock Insight & Charts - FinViz.com||View IBB Investment Charts - StockCharts.com|
|View IBB Stock Overview & Charts - BarChart||View IBB User Generated Charts - Trading View|
Gemphire Therapeutics stock plunges after trial halted due to 'unanticipated problems'
Posted on Friday August 10, 2018
Shares of Gemphire Therapeutics Inc. (gemp) plunged 17% toward a record low Friday after the biopharmaceutical company said a phase 2a trial of its treatment for non-alcoholic fatty liver disease in pediatric patients will be terminated, citing "unanticipated problems." The company said the data and safety monitoring board at Emory University overseeing the trial recommended the termination. Gemphire said data on the first three patients undergoing 12 weeks of treatment all experienced an increase in liver fat content, which was deemed an unexpected problem.
BeiGene’s Q2 2018 Earnings: Reports Revenue Growth
Posted on Thursday August 09, 2018
BeiGene (BGNE) released its second-quarter earnings on August 9. The company surpassed Wall Street analysts’ estimates for revenues but missed its EPS estimates. BeiGene reported adjusted EPS of -$2.92 on revenues of $52.8 million, compared to its estimated EPS of -$2.06 on revenues of $22.5 million. The chart below compares BeiGene’s revenues and EPS since the first quarter of 2017.
How Ionis’s Q2 2018 Earnings Trended
Posted on Wednesday August 08, 2018
Ionis Pharmaceuticals (IONS), one of the leading biopharmaceutical companies, is focused on developing RNA-targeted therapies. Ionis has developed many drugs for the treatment of various life-threatening diseases through its broadly applicable drug discovery platform. Ionis missed Wall Street analyst estimates and reported earnings per share of -$0.29 on revenues of $117.7 million during Q2 2018 as compared to EPS estimates of -$0.09 on revenues of $135.5 million during the quarter.
Ampio's stock plunges below $1 threshold after FDA comments on clinical trial
Posted on Wednesday August 08, 2018
Shares of Ampio Pharmaceuticals Inc. (ampe) plunged 69% in morning trade Wednesady, to fall back below the $1 threshold for the first time in 10 months, after the biopharmaceutical company said the Food and Drug Administration said a current trial for a treatment of osteoarthritis of the knee did not support a biologics license application (BLA). The FDA said the that as a single trial, the AP-003-A trial on its own does not appear to provide sufficient evidence of effectiveness to support a BLA. The FDA recommended an additional randomized trial.